Allakos LLC, formerly known as Allakos Inc. is a biotechnology company. The Company is developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 16:00:00 2025-05-14 EDT			5-day change	1st Jan Change
0.3291 ^USD	-0.06%		-.--%	-

25-05-15	Allakos Inc. Announces Resignation of Dr. Robert Alexander as CEO	CI
25-05-15	Allakos Inc. Announces Resignation of Baird Radford as CFO	CI

Market Cap	29.74M 25.92M 23.89M 22.47M 42.04M 2.8B 42.33M 284M 110M 1.38B 112M 109M 4.79B	P/E 2023	-1.28x	P/E 2024	-0.93x
Enterprise Value	-46.92M -40.88M -37.68M -35.45M -66.31M -4.42B -66.78M -448M -174M -2.18B -176M -172M -7.55B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	96.57%	Yield 2023 *	-	Yield 2024	-

25-05-15	Allakos Inc. Announces Resignation of Dr. Robert Alexander as CEO	CI
25-05-15	Allakos Inc. Announces Resignation of Baird Radford as CFO	CI
25-05-15	Allakos Inc. Announces Executive Changes	CI
25-05-14	Allakos Inc.(NasdaqGS:ALLK) dropped from NASDAQ Composite Index	CI
25-05-14	Concentra Biosciences, LLC completed the acquisition of Allakos Inc..	CI
25-05-08	Allakos Inc.(NasdaqGS:ALLK) dropped from S&P TMI Index	CI
25-05-07	Allakos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-02	Allakos to Be Acquired by Concentra Biosciences for $0.33 per Share	MT
25-04-02	Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences	RE
25-04-01	Concentra Biosciences, LLC entered into an agreement to acquire Allakos Inc. for $31 million.	CI
25-03-12	Allakos Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
25-03-12	Allakos Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	CI
25-01-27	Top Midday Decliners	MT

24-01-17	Barclays Trims Allakos' Price Target to $1 From $1.50, Maintains Underweight Rating	MT
24-01-17	JMP Securities Adjusts Allakos' Price Target to $3 From $10, Maintains Market Outperform Rating	MT
24-01-17	Jefferies Downgrades Allakos to Hold From Buy, Adjusts Price Target to $1.50 From $6	MT
24-01-16	Cantor Fitzgerald Downgrades Allakos to Neutral From Overweight	MT
24-01-16	Lifesci Capital Downgrades Allakos to Market Perform From Outperform	MT

Allakos Inc. Stock

Stocks

ALLK

US01671P1003

Biotechnology & Medical Research

Valuation: Allakos Inc.

Latest news : Allakos Inc.

Analysts' recommendations: Allakos Inc.

Press Releases: Allakos Inc.

News in other languages: Allakos Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Allakos Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

22-07-22	Lonza-Aktien sinken nach Halbjahreszahlen
19-12-05	EN DIRECT DES MARCHES : Kering / Moncler, FDJ, Engie, Capgemini, Cybergun, Amazon, Fiat Chrysler...
19-12-05	Des marchés moins cyclothymiques pour finir la semaine ?

Date	Insider	Type	Main position	Quantity	% Market Cap.
25-05-14	Robert Alexander	Issuer sale	Chief Executive Officer	5,280,211	5.9100%
25-05-14	NEA Management Co. LLC	Issuer sale	Company	6,147,260	6.8805%
25-05-14	Steven James	Issuer sale	Director	332,932	0.3726%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALLAKOS INC.	-0.06%	-.--%	-.--%	-92.94%	29.74M
LONZA GROUP AG	+1.27%	+1.37%	-10.93%	-9.47%	42.75B
REVOLUTION MEDICINES, INC.	+3.31%	+9.22%	+308.19%	+562.02%	34.65B
BEONE MEDICINES AG	+2.84%	+3.80%	+6.87%	+34.93%	30.03B
IQVIA HOLDINGS INC.	-1.70%	-7.34%	+8.51%	-22.34%	28B
CELLTRION, INC.	-0.57%	+4.45%	+12.31%	+20.42%	24.83B
ASCENDIS PHARMA A/S	-0.14%	+7.06%	-	-	14.34B
MEDPACE HOLDINGS, INC.	+0.68%	-3.13%	+52.04%	+107.47%	13.14B
EUROFINS SCIENTIFIC SE	-0.45%	-2.31%	+5.32%	+4.33%	12.61B
IONIS PHARMACEUTICALS, INC.	-0.26%	+0.41%	+100.27%	+80.69%	12.25B
Average	+0.49%	+0.80%	+53.62%	+76.12%	21.26B
Weighted average by Cap.	+0.90%	+1.27%	+65.26%	+113.23%

	2023	2024
Net sales	-	-
Net income	-186M -162M -149M -140M -262M -17.5B -264M -1.77B -689M -8.62B -697M -682M -29.89B	-116M -101M -93.02M -87.5M -164M -10.92B -165M -1.11B -430M -5.38B -435M -425M -18.64B
Net Debt	-129M -113M -104M -97.71M -183M -12.19B -184M -1.24B -480M -6.01B -485M -475M -20.82B	-76.66M -66.8M -61.57M -57.92M -108M -7.23B -109M -733M -285M -3.56B -288M -282M -12.34B

3 years	0.22	5.64
5 years	0.22	112.87
10 years	0.22	157.98